Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics’ AI-driven epigenetic-genetic tests, marking a new era in personalized and preventive cardiac care.

CHICAGO–(BUSINESS WIRE)–In a significant stride towards transforming cardiovascular healthcare in concierge specialty and primary care offices, Exponential Health, an innovative concierge medical practice led by Dr. William Baer, is set to offer Cardio Diagnostics Holdings, Inc.’s (Nasdaq: CDIO) clinical epigenetic-genetic cardiovascular tests, Epi+Gen CHD and PrecisionCHD, to their patients. As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Exponential Health emphasizes a more personalized and patient-centric approach to preventive care. Its value-based care model allows Exponential Health to dedicate more time to each patient, conducting comprehensive assessments and creating tailored preventive care plans for them.

A Synergy of Innovation and Expertise in Precision Care

The U.S. concierge medicine market size was estimated to be at USD 6.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.37% from 2024 to 2030, reaching USD 13.3 billion. This growth is driven by increasing demand for convenient care, advantages offered by concierge medicine to patients, and higher career satisfaction among concierge physicians.

Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions. This partnership combines advanced medical technologies with unparalleled and personalized clinical expertise, setting a new benchmark for concierge practices enhancing preventive cardiology in primary care. Exponential Health aims to proactively identify and monitor patients using Cardio Diagnostics’ solutions to intervene with an innovative framework for early assessment, diagnosis, and management of coronary heart disease, which is the most common type of heart disease and the primary cause of heart attacks. The practice offers patients a more personalized healthcare journey.

Dr. William Baer, Founder of Exponential Health, expressed enthusiasm about the collaboration, stating, “Our alliance with Cardio Diagnostics is a testament to our dedication to embracing innovative solutions that enhance patient care. Their advanced cardiovascular tests will empower us to detect and address heart disease with unprecedented precision, aligning perfectly with our mission to deliver superior, individualized care.”

Cardio Diagnostics’ cutting-edge tests, Epi+Gen CHD and PrecisionCHD, are designed to assess the risk of coronary heart disease events and aid in diagnosing coronary heart disease, respectively, using a blend of genomics, epigenomics, and artificial intelligence. These tests coupled to Cardio Diagnostics’ Actionable Clinical Intelligence platform can provide critical insights into a patient’s cardiovascular health at the molecular level, enabling earlier intervention and tailored treatment strategies with higher precision.

Transforming Cardiovascular Health Management

“We are thrilled to partner with Dr. Baer and Exponential Health,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “This partnership is a powerful demonstration of our shared commitment to advancing cardiovascular health through innovation. By integrating our precision medicine solutions into Exponential Health’s practice, we are poised to make a significant impact on preventing heart disease and improving outcomes for patients.”

This collaboration arrives at a pivotal moment, as cardiovascular disease remains the leading cause of death globally. Integrating Cardio Diagnostics’ advanced tests into Exponential Health’s offerings is a proactive step toward mitigating this global health challenge. It will provide patients with access to state-of-the-art diagnostic tools that facilitate informed decision-making and personalized prevention plans.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

About Exponential Health

Exponential Health is a leading concierge medical practice that prioritizes preventive medicine and early detection to optimize health and wellness. Founded by Dr. William Baer, a pioneer in preventive and personalized medicine, Exponential Health leverages cutting-edge technology and customized care to revolutionize the healthcare experience and empower patients to achieve their best health outcomes.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act 1995. When used in this press release, the words or phrases “will,” “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022, and Forms 10-Q for the period ended March 31, 2023, and September 30, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Contacts

Investors:
Gene Mannheimer

Investor Relations

855-226-9991

investors@cardiodiagnosticsinc.com

Media & Public Relations:
Khullani Abdullahi

855-226-9991

pr@cardiodiagnosticsinc.com